Telehealth Support for Artificial Respiration
(TEACH Trial)
Trial Summary
What is the purpose of this trial?
This trial is testing a telehealth system called 'TEACH' to help doctors and nurses better manage the process of waking up and helping patients on ventilators breathe on their own. The goal is to improve patient outcomes by making it easier for healthcare providers to follow best practices.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
What data supports the effectiveness of the treatment Telehealth-enabled support for SAT/SBT adherence?
Research shows that telehealth technologies can improve adherence to treatment plans, as seen in studies with lung transplant recipients and COPD patients. These technologies help maintain high levels of adherence by providing immediate feedback, reminders, and simplifying communication between patients and healthcare providers.12345
Is telehealth support for artificial respiration generally safe for humans?
The research on telehealth systems for managing conditions like asthma and transplant adherence shows that these systems are generally well-accepted and safe, with participants finding them helpful and easy to use. No significant safety concerns were reported in the studies, and participants often experienced improved adherence and satisfaction with the telehealth interventions.16789
How is the Telehealth-enabled support for SAT/SBT adherence treatment different from other treatments for artificial respiration?
The Telehealth-enabled support for SAT/SBT adherence treatment is unique because it uses telehealth technology to enhance adherence to artificial respiration protocols by providing immediate feedback, reminders, and educational support, which can help maintain high adherence levels over time, unlike traditional methods that may not offer such interactive and continuous support.110111213
Research Team
Colin Grissom, MD
Principal Investigator
Intermountain Health Care, Inc.
Eligibility Criteria
This trial is for patients aged 16 or older who are in the ICU and on artificial breathing support. It's not for those who passed away within a day of being put on a ventilator or were already brain dead when admitted for organ donation.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive coordinated spontaneous awakening and breathing trials with telehealth-enabled support or usual audit and feedback
Follow-up
Participants are monitored for ventilator-free days and other clinical outcomes
Treatment Details
Interventions
- Telehealth-enabled support for SAT/SBT adherence (Behavioural Intervention)
- Usual audit and feedback for SAT/SBT adherence (Behavioural Intervention)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Intermountain Health Care, Inc.
Lead Sponsor
Brent James
Intermountain Health Care, Inc.
Chief Medical Officer since 2010
MD from University of Utah
Rob Allen
Intermountain Health Care, Inc.
Chief Executive Officer since 2022
Bachelor's degree in Business Administration
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator
Dr. Gary H. Gibbons
National Heart, Lung, and Blood Institute (NHLBI)
Chief Executive Officer since 2012
MD from Harvard Medical School
Dr. James P. Kiley
National Heart, Lung, and Blood Institute (NHLBI)
Chief Medical Officer since 2011
MD from University of California, San Francisco
University of Utah
Collaborator
Jeffrey Wilkins
University of Utah
Chief Medical Officer since 2022
MD from Meharry Medical College
Stephen Tullman
University of Utah
Chief Executive Officer since 2022
BS in Accounting from Rutgers University